Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Palantir Technologies

Riot Blockchain

These companies used to be flying high, but fortunes can change quickly on Wall Street. Now they're stocks that could crash soon.

4 Stocks That Could Crash Soon

They're key as its coronavirus vaccine candidate approaches possible commercialization.

These 2 Elements in Novavax's Earnings Report Could Mean Billions for the Biotech

Poland-based biotech firm Mabion has signed a preliminary agreement to manufacture Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, reports Bloomberg. The polish company will get 40 million zlotys ($11 million) in loans and equity from a state-run fund to support doubling its production capacity in Poland.

Novavax Partners With Poland's Mabion For COVID-19 Vaccine Production: Bloomberg

Only details about the diversity of participants have been released at this point.

Novavax's COVID Vaccine Trial: Are There Any Yellow Flags So Far?

Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.

Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates

Hint: It wasn't the biotech's all-time best top line or the all-time worst bottom line.

What Really Mattered With Novavax's Q4 Update

Novavax CEO Stanley Erck has predicted the company's coronavirus vaccine could be authorized in the US as early as May. Trial results suggest the vaccine is highly effective, though less so against the variant first found in South Africa, which has spread to at least 10 US states including New York.

Novavax's COVID-19 vaccine could be authorized as early as May, its CEO said. A trial suggests it is 89% effective, although slightly less so against contagious variants.

Stanley Erck said his company will have at least tens of millions of doses available if and when it's granted authorization.

Novavax CEO Says Its Coronavirus Vaccine Could Win FDA Approval in May

Novavax, Inc. (NVAX) CEO Stan Erck on Q4 2020 Results - Earnings Call Transcript

The vaccine developer aims to supply 2 billion doses a year.

Novavax Hopes to Start Supplying Covid Shots This Spring

Zoom Video

The Dow rose 1.95% on the day, +603 points; the S&P 500 gained 2.38%; the Nasdaq rose 3%, nearly 400 points; and the small-cap Russell 2000 took the cake, +3.37%.

Markets Up Big Monday; Zoom (ZM) Beats, Novavax (NVAX) Misses Q4

Novavax Inc. (NASDAQ: NVAX) said on Monday that its sales in the fiscal fourth quarter beat Wall Street estimates. The company, however, swung to a quarterly loss that was broader than what analysts had anticipated.

Novavax swings to a broader than expected loss in the fourth quarter

Roku

Inovio Pharmaceuticals

These are the stocks posting the largest moves after the bell on Monday, March 1.

Stocks making the biggest moves after the bell: Zoom, Roku, Novavax & more

The Food and Drug Administration could authorize Novavax's Covid-19 for emergency use as early as May, the company's CEO, Stanley Erck, told CNBC.

Novavax expects FDA clearance for Covid vaccine as early as May, CEO says

Shares of Novavax (NASDAQ:NVAX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 138.94% over the past year to ($2.70), which missed the estimate of ($1.49).

Novavax: Q4 Earnings Insights

Shares of Novavax Inc. wavered between gains and losses in the extended session Monday after the biotech company reported a wider-than-expected fourth-quarter loss but its sales beat Wall Street expectations. Novavax said it lost $177.6 million, or $2.70 a share, in the quarter, compared with a net loss of $31.8 million, or $1.13 a share, for the fourth quarter of 2019.

Novavax posts wider quarterly loss, sales jump due to pandemic-related services

Novavax Inc's chief executive said on Monday its COVID-19 vaccine could be cleared for use in the United States as soon as May if U.S. regulators authorize it based on data from the company's British trial, which could be completed as soon as April.

Novavax COVID-19 shot could be cleared for U.S. use as early as May: CEO

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2020.

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Digital Turbine

Community Health Systems

Inari Medical

Retractable Technologies

Bancorp

Veritone

VirnetX

XBiotech

These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.

Top Small-Cap Stocks for March 2021

GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda's development, manufacturing and commercialization of NVX-CoV2373, Novavax' COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax' vaccine candidate in the Japanese population.

Novavax and Takeda Finalize License Agreement for Novavax' COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

Novavax said in January its coronavirus vaccine was 89.3% effective in a Phase 3 test. It's also effective against variants.

Novavax Surges Again On Vaccine Supply Deal; Is NVAX Stock A Buy?

Johnson & Johnson

Both companies tested their vaccine candidates as new variants rapidly spread.

Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?

The Novavax Covid vaccine has the highest efficacy against the original Covid-19 strain and the South Africa variant. It is also the only vaccine with proven efficacy against 3 variants. It is the only major Covid vaccine that can easily be made into a multivalent vaccine that contains multiple variants in a single dose.

12 Reasons Novavax Beats Pfizer For Titles Of Best Covid Vaccine And Best Covid Vaccine Stock

They both have to do with the company's COVID-19 vaccine candidate.

Here Are the 2 Most Important Things to Look for in Novavax's Earnings Report Next Week

Takeda Pharmaceutical

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical trial. The first volunteer was given a Novavax shot in a Phase 1/2 immunogenicity and safety trial of 200 adult volunteers in Japan.

News for Novavax Stock (NVAX)